Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2614367 | 0.81 | ALOX15 (0.59) | ALOX15L3MBTL1NPC1KDM4EGAA | |
| SCHEMBL855532 | 0.76 | ALOX15 (1.00) | ALOX15L3MBTL1NPC1KDM4EMEN1 | |
| SCHEMBL23529733 | 0.75 | L3MBTL1 (0.46) | ALOX15L3MBTL1NPC1KDM4EPDE10A | |
| SCHEMBL646282 | 0.70 | ALOX15 (0.47) | ALOX15L3MBTL1NPC1KDM4EGAA | |
| SCHEMBL11983700 | 0.69 | CCR1 (0.57) | ALOX15NPC1KDM4EGAAHSD17B10 | |
| SCHEMBL439225 | 0.69 | KDM4E (0.49) | ALOX15NPC1KDM4EPDE10AGAA | |
| SCHEMBL197196 | 0.68 | PCSK9 (0.60) | ALOX15NPC1KDM4EGAAHSD17B10 | |
| SCHEMBL19374774 | 0.68 | NPC1 (0.68) | ALOX15L3MBTL1NPC1KDM4EPDE10A | |
| SCHEMBL427627 | 0.67 | L3MBTL1 (1.00) | L3MBTL1NPC1KDM4EPDE10AGAA | |
| SCHEMBL18027880 | 0.67 | L3MBTL1 (0.59) | ALOX15L3MBTL1NPC1KDM4EPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095044-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | Sanford-Burnham Medical Research Institute California | 2012-04-19 | — | — | US | disclosed |
| US-8119693-B2 | Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090156560-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095044-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | ALPL, CNDP2, ALPI | ALOX15 2411/4885L3MBTL1 3864/4885NPC1 2886/4885 |
| US-20090156560-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | ALPL, CNDP2, ALPI | ALOX15 2411/4885L3MBTL1 3864/4885NPC1 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.